Metreleptin for treating lipodystrophy

the recommendations in this evaluation within 3 months of its date of publication. 5.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE highly specialised technologies guidance. When a NICE highly specialised technologies guidance recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final evaluation document. 5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraph above. This means that, if a patient has lipodystrophy and the doctor responsible for their care thinks that metreleptin is the right treatment, it should be available for use, in line with NICE's recommendations.
